<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377362</url>
  </required_header>
  <id_info>
    <org_study_id>GLWL-SMP</org_study_id>
    <nct_id>NCT02377362</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01</brief_title>
  <official_title>A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, and Proof of Concept Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GLWL Research Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GLWL Research Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 3-part study will explore the safety and tolerability of GLWL-01 in overweight/obese
      healthy participants after single doses (in Part A), and in participants with type 2 diabetes
      mellitus after multiple doses during a 28-day period (Parts B and C).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient efficacy for this indication. The study stopped after Part B.
  </why_stopped>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">November 9, 2016</completion_date>
  <primary_completion_date type="Actual">November 9, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With One or More Treatment Emergent Adverse Events (Part A)</measure>
    <time_frame>Baseline to 7 weeks</time_frame>
    <description>Treatment Emergent Adverse Event defined as an adverse event that started or worsened in severity at the time of, or after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With One or More Treatment Emergent Adverse Events (Parts B)</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Treatment Emergent Adverse Event defined as an adverse event that started or worsened in severity at the time of, or after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Non-Zero Concentration (AUC0-t) (Part A)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Non-Zero Concentration (AUC0-t) (Part B)</measure>
    <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to 24-hour Post-Dose (AUC0-24) (Part A)</measure>
    <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to 24-hour Post-Dose (AUC0-24) (Parts B)</measure>
    <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24 hours post dose starting on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) (Part A)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) (Part B)</measure>
    <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax) (Part A)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax) (Part B)</measure>
    <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Observed Cmax (Tmax) (Part A)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Observed Cmax (Tmax) (Part B)</measure>
    <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-Life (T1/2) (Part A)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-Life (T1/2) (Part B)</measure>
    <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance of Drug (CL/F) (Part A)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance of Drug (CL/F) (Part B)</measure>
    <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Volume of Distribution (VZ/F) (Part A)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Volume of Distribution (VZ/F) (Part B)</measure>
    <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Drug Excreted in Urine (Aet1-t12) (Part A)</measure>
    <time_frame>Pre-Dose and 12 hours Post-Dose</time_frame>
    <description>Data Not Collected for this Parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Drug Excreted in Urine (Aet1-t12) (Part B)</measure>
    <time_frame>Pre-Dose and 12 hours Post-Dose on Day 28</time_frame>
    <description>Data Not Collected for this Parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Drug Excreted in Urine (Aet0-24) (Part A)</measure>
    <time_frame>Pre-Dose and 24-hours Post-Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Drug Excreted in Urine (Aet0-24) (Part B)</measure>
    <time_frame>Pre-Dose and 24-hours Post-Dose on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of Drug Excreted in the Urine (Fe) (Part A)</measure>
    <time_frame>Pre-Dose and 24-hours Post-Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of Drug Excreted in the Urine (Fe) (Part B)</measure>
    <time_frame>Pre-Dose and 24-hours Post-Dose on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Plasma Glucose Concentration After Multiple Doses (Part B)</measure>
    <time_frame>Baseline to Day 24-26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postprandial Glucose (Part B)</measure>
    <time_frame>Day 28</time_frame>
    <description>Mixed Meal Tolerance Test (4.5 hours after a meal on Day 28); Baseline Adjusted. The day 28 values were used for analysis; change from baseline was calculated on Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-Peptide Concentration (Part B)</measure>
    <time_frame>Day 28</time_frame>
    <description>Mixed Meal Tolerance Test (4.5 hours after a meal on Day 28); Baseline-Adjusted. The day 28 values were used for analysis; change from baseline was calculated on Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin Concentration (Part B)</measure>
    <time_frame>Day 28</time_frame>
    <description>4.5 hours following Mixed Meal Tolerance Test (MMTT) on Day 28; Baseline Adjusted. The day 28 values were used for analysis; change from baseline was calculated on Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose Concentration (Part B)</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Fasting glucose concentration after 28 day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weight (Part B)</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist Circumference (Part B)</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hip Circumference (Part B)</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>GLWL-01, Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose in at least 2 of 3 periods, starting at 10 milligrams (mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Part A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Escalating dose of placebo to match GLWL-01, in 1 period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLWL-01, Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending daily doses of GLWL-01 at up to six dose levels, based on Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple daily doses of placebo to match GLWL-01</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLWL-01, Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple daily doses of GLWL-01 at level based upon Part B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Part C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple daily doses of placebo to match GLWL-01</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLWL-01, Part A</intervention_name>
    <description>Capsules administered orally, in 2 out of 3 periods</description>
    <arm_group_label>GLWL-01, Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, Part A</intervention_name>
    <description>Capsules administered orally in 1 out of 3 periods</description>
    <arm_group_label>Placebo, Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLWL-01, Part B</intervention_name>
    <description>Capsules administered orally either once or twice daily for 27 days, with a single dose on Day 28</description>
    <arm_group_label>GLWL-01, Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, Part B</intervention_name>
    <description>Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
    <arm_group_label>Placebo, Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLWL-01, Part C</intervention_name>
    <description>Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
    <arm_group_label>GLWL-01, Part C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, Part C</intervention_name>
    <description>Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
    <arm_group_label>Placebo, Part C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        PARTS A-C:

          -  Non-vasectomized males (or those vasectomized less than 4 months prior to study start)
             must agree to use a condom with spermicide or abstain from sexual intercourse during
             the study until 90 days beyond the last dose of study drug

          -  Males agree to not donate sperm from dosing until 90 days after dosing

          -  Laboratory test results within normal range or acceptable deviation, and Aspartate
             Aminotransferase (AST) / Alanine Aminotransferase (ALT) / Gamma Glutamyl Transferase
             (GGT) / Alkaline Phosphatase (ALP) to be less than or equal to (≤)1.5 x upper limit of
             normal (ULN), and total bilirubin has to be within normal limit

          -  Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 60 milliliter
             (mL)/minute/1.73m2

          -  No evidence of weight excursion beyond 5% of baseline weight within 3 months of
             screening

        PART A Only:

          -  Overtly healthy males or females, as determined by medical history and physical
             examination

          -  Males must be 18 to 65 years old; females must be 40 to 65 years old

          -  Female participants must be:

               1. Women with prior history of hysterectomy who are at least 45 years of age and
                  with follicle-stimulating hormone (FSH) greater than (&gt;) 40 milli-international
                  units per milliliter (mIU/mL), or

               2. Menopausal women with either: spontaneous amenorrhea for at least 12 months (not
                  induced by a medical condition or medications); or spontaneous amenorrhea for 6
                  to 12 months and a FSH &gt; 40 mIU/mL

          -  Body mass index (BMI) of 28 to 35 kilograms divided by height in meters squared
             (kg/m2)

          -  Normotensive (supine systolic blood pressure (BP) less than (&lt;) 140 millimeter of
             mercury (mmHg) and diastolic BP &lt;90 mmHg

          -  No evidence of weight excursion beyond 5% of baseline weight within 3 months of
             screening

        PARTS B and C:

          -  Must have Type 2 Diabetes Mellitus

          -  Be 18 to 70 years old

          -  Have BMI of 28 to 42 kg/m2

          -  Female participants must be of non-childbearing potential, and must have undergone one
             of the following sterilization procedures at least 6 months prior to first dose:
             hysteroscopic sterilization, bilateral tubal ligation or bilateral salpingectomy,
             hysterectomy, or bilateral oophorectomy; or be postmenopausal with amenorrhea for at
             least 1 year prior to the first dose and with FSH serum levels consistent with
             postmenopausal status

          -  Normotensive (supine systolic BP) &lt; 150 mmHg and diastolic BP &lt;95 mmHg or
             well-controlled hypertension while on a stable hypertensive

        Exclusion Criteria:

        PARTS A-C:

          -  Currently enrolled in a clinical trial or any other medical research judged to be not
             compatible with the study, or have participated in the last 30 days prior to dosing in
             a clinical trial involving an investigational product or non-approved use of a drug
             with short half-life, or within 5 half-lives of an investigational product with a
             half-life longer than 6 days

          -  Abnormality in the 12-lead electrocardiogram (ECG) including corrected QT (QTc)
             interval with Bazett's correction &gt;450 milliseconds (msec) for men and &gt;470 msec for
             women, or an abnormality that, in the opinion of the Investigator, increases the risks
             associated with participating in the study

          -  Significant cardiovascular disease or other disorders

          -  Evidence of human immunodeficiency virus (HIV) infection, hepatitis B, hepatitis C, or
             other chronic liver or biliary disease

          -  Average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per
             week (females), or is unwilling to stop use of Cytochrome P450 (CYP3A)
             inhibitors/inducers (St. John's Wort) or alcohol consumption for the study, or regular
             use of known drugs of abuse or positive finding on urinary drug screen, use of
             cigarettes or nicotine products within last 3 months, or blood donation or loss within
             56 days prior to the study

          -  Neuropsychiatric disease or pharmacological therapy for such conditions within 1 year
             of dosing, or antidepressants or antipsychotics within 3 months of dosing, or surgery
             within last 60 days

          -  Eating disorder or weight loss medications within 4 months of dosing, or bariatric
             surgery

          -  Unsuitable for inclusion in the study in the opinion of the investigator or sponsor

        PART A Only:

          -  History of hypertension (or on treatment with any antihypertensives)

          -  Endocrine illness such as diabetes, growth hormone insufficiency / acromegaly, adrenal
             gland or thyroid illness

        PARTS B and C:

          -  Currently taking simvastatin &gt; 10 mg per day, or atorvastatin &gt; 20 mg per day, or
             lovastatin &gt;20 mg per day, or history of statin-induced myopathy / rhabdomyolysis.
             Participants taking any dose of simvastatin will be excluded from some cohorts

          -  Allergic to the components of the Mixed Meal Tolerance Test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email choruspharma@lists.lilly.com</last_name>
    <role>Study Director</role>
    <affiliation>GLWL Research Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <results_first_submitted>November 30, 2017</results_first_submitted>
  <results_first_submitted_qc>March 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 21, 2019</results_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Part A was a 3-period crossover design. Part A participants were to receive 2 escalating single doses of study drug and one dose of placebo. Part B participants were randomized to multiple doses of study drug or placebo. The study was stopped after Part B.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GLWL-01, Part A (Placebo; 150 mg; 600 mg)</title>
          <description>Part A: Cohort 1(C1) Sequence 1 (Placebo, 150 mg, 600 mg)
Placebo was taken orally first intervention, then 150 mg GLWL 01 was taken orally second intervention, then 600 mg GLWL 01 was taken orally third intervention.</description>
        </group>
        <group group_id="P2">
          <title>GLWL-01, Part A (10 mg; Placebo; 600 mg)</title>
          <description>Part A: Cohort 1(C1) Sequence 2 (10 mg, Placebo, 600 mg)
10 mg GLWL 01 was taken orally first intervention, then Placebo was taken orally second intervention, then 600 mg GLWL 01 was taken orally third intervention.</description>
        </group>
        <group group_id="P3">
          <title>GLWL-01, Part A (10 mg; 150 mg; Placebo)</title>
          <description>Part A: Cohort 1(C1) Sequence 3 (10 mg, 150 mg, Placebo)
10 mg GLWL 01 was taken orally first intervention, then 150 mg GLWL 01 was taken orally second intervention, then Placebo was taken orally third intervention.</description>
        </group>
        <group group_id="P4">
          <title>GLWL-01, Part A (Placebo; 300 mg; 1200 mg)</title>
          <description>Part A: Cohort 2(C2) Sequence 1 (Placebo, 300 mg, 1200 mg)
Placebo was taken orally first intervention, then 300 mg GLWL 01 was taken orally second intervention, then 1200 mg GLWL 01 was taken orally third intervention</description>
        </group>
        <group group_id="P5">
          <title>GLWL-01, Part A (50 mg, Placebo; 1200 mg)</title>
          <description>Part A: Cohort 2(C2) Sequence 2 (50 mg, Placebo, 1200 mg)
50 mg GLWL 01 was taken orally first intervention, then Placebo was taken orally second intervention, then 1200 mg GLWL 01 was taken orally third intervention</description>
        </group>
        <group group_id="P6">
          <title>GLWL-01, Part A ( 50 mg; 300 mg; Placebo)</title>
          <description>Part A: Cohort 2(C3) Sequence 3 (50 mg, 300 mg, Placebo)
50 mg GLWL 01 was taken orally first intervention, then 300 mg GLWL 01 was taken orally second intervention, then Placebo was taken orally third intervention.</description>
        </group>
        <group group_id="P7">
          <title>GLWL-01, Part B (50 mg, Twice a Day)</title>
          <description>Multiple oral doses
Part B: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
        </group>
        <group group_id="P8">
          <title>GLWL-01, Part B (150 mg Twice a Day)</title>
          <description>Multiple oral doses
Part B: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
        </group>
        <group group_id="P9">
          <title>GLWL-01, Part B (300 mg Once a Day)</title>
          <description>Multiple oral doses
Part B: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
        </group>
        <group group_id="P10">
          <title>GLWL-01, Part B (450 mg Once a Day)</title>
          <description>Multiple oral doses
Part B: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
        </group>
        <group group_id="P11">
          <title>GLWL-01, Part B, (450 mg Twice a Day)</title>
          <description>Multiple oral doses
Part B: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
        </group>
        <group group_id="P12">
          <title>GLWL-01, Part B (600 mg Twice a Day)</title>
          <description>Multiple oral doses
Part B: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
        </group>
        <group group_id="P13">
          <title>Placebo, Part B</title>
          <description>Multiple oral doses of placebo to match GLWL-01
Placebo, Part B: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A First Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A Second Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part A Third Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Highest dose level 1200 not used</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B Overall</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="7"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>.Part A was a crossover design. Part A participants were to receive 2 escalating doses of study drug and one dose of placebo in 3 periods.</population>
      <group_list>
        <group group_id="B1">
          <title>GLWL-01, Part A (Placebo; 150 mg; 600 mg)</title>
          <description>Part A: Cohort 1(C1) Sequence 1 (Placebo, 150 mg, 600 mg)
Placebo was taken orally first intervention, then 150 mg GLWL 01 was taken orally second intervention, then 600 mg GLWL 01 was taken orally third intervention</description>
        </group>
        <group group_id="B2">
          <title>GLWL-01, Part A (10 mg; Placebo; 600 mg)</title>
          <description>Part A: Cohort 1(C1) Sequence 2 (10 mg, Placebo, 600 mg)
10 mg GLWL 01 was taken orally first intervention, then Placebo was taken orally second intervention, then 600 mg GLWL 01 was taken orally third intervention.</description>
        </group>
        <group group_id="B3">
          <title>GLWL-01, Part A (10 mg; 150 mg; Placebo)</title>
          <description>Part A: Cohort 1(C1) Sequence 3 (10 mg, 150 mg, Placebo)
10 mg GLWL 01 was taken orally first intervention, then 150 mg GLWL 01 was taken orally second intervention, then Placebo was taken orally third intervention</description>
        </group>
        <group group_id="B4">
          <title>GLWL-01, Part A (Placebo; 300 mg; 1200 mg)</title>
          <description>Part A: Cohort 2(C2) Sequence 1 (Placebo, 300 mg, 1200 mg)
Placebo was taken orally first intervention, then 300 mg GLWL 01 was taken orally second intervention, then 1200 mg GLWL 01 was taken orally third intervention</description>
        </group>
        <group group_id="B5">
          <title>GLWL-01 Part A (50 mg, Placebo; 1200 mg)</title>
          <description>Part A: Cohort 2(C2) Sequence 2 (50 mg, Placebo, 1200 mg)
50 mg GLWL 01 was taken orally first intervention, then Placebo was taken orally second intervention, then 1200 mg GLWL 01 was taken orally third intervention</description>
        </group>
        <group group_id="B6">
          <title>GLWL-01, Part A ( 50 mg; 300 mg; Placebo)</title>
          <description>Part A: Cohort 2(C3) Sequence 3 (50 mg, 300 mg, Placebo)
50 mg GLWL 01 was taken orally first intervention, then 300 mg GLWL 01 was taken orally second intervention, then Placebo was taken orally third intervention</description>
        </group>
        <group group_id="B7">
          <title>GLWL-01, Part B (50 mg Twice a Day)</title>
          <description>Multiple oral doses
Part B: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
        </group>
        <group group_id="B8">
          <title>GLWL-01, Part B (150 mg Twice a Day)</title>
          <description>Multiple oral doses
Part B: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
        </group>
        <group group_id="B9">
          <title>GLWL-01, Part B (300 mg Once a Day)</title>
          <description>Multiple oral doses
Part B: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
        </group>
        <group group_id="B10">
          <title>GLWL-01, Part B (450 mg Once a Day)</title>
          <description>Multiple oral doses
Part B: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
        </group>
        <group group_id="B11">
          <title>GLWL-01, Part B (450 mg Twice a Day)</title>
          <description>Multiple oral doses
Part B: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
        </group>
        <group group_id="B12">
          <title>GLWL-01, Part B (600 mg Twice a Day)</title>
          <description>Multiple oral doses
Part B: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
        </group>
        <group group_id="B13">
          <title>Placebo, Part B</title>
          <description>Multiple daily doses of placebo to match GLWL-01
Placebo, Part B: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28</description>
        </group>
        <group group_id="B14">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="7"/>
            <count group_id="B11" value="6"/>
            <count group_id="B12" value="7"/>
            <count group_id="B13" value="12"/>
            <count group_id="B14" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="10"/>
                    <measurement group_id="B14" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="12"/>
                    <measurement group_id="B14" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="11"/>
                    <measurement group_id="B14" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="12"/>
                    <measurement group_id="B14" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Treatment Emergent Adverse Events (Part A)</title>
        <description>Treatment Emergent Adverse Event defined as an adverse event that started or worsened in severity at the time of, or after treatment</description>
        <time_frame>Baseline to 7 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part A (10mg)</title>
            <description>10 milligrams (mg)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part A (50 mg)</title>
            <description>50 mg</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part A (150 mg)</title>
            <description>150 mg</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part A (300 mg)</title>
            <description>300 mg</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part A (600 mg)</title>
            <description>600 mg</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part A Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Treatment Emergent Adverse Events (Part A)</title>
          <description>Treatment Emergent Adverse Event defined as an adverse event that started or worsened in severity at the time of, or after treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Treatment Emergent Adverse Events (Parts B)</title>
        <description>Treatment Emergent Adverse Event defined as an adverse event that started or worsened in severity at the time of, or after treatment</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50 mg, Twice a Day)</title>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
          </group>
          <group group_id="O7">
            <title>GLWL-01 Part B Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Treatment Emergent Adverse Events (Parts B)</title>
          <description>Treatment Emergent Adverse Event defined as an adverse event that started or worsened in severity at the time of, or after treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Non-Zero Concentration (AUC0-t) (Part A)</title>
        <time_frame>Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part A (10mg)</title>
            <description>10 milligrams (mg)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part A (50 mg)</title>
            <description>50 mg</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part A (150 mg)</title>
            <description>150 mg</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part A (300 mg)</title>
            <description>300 mg</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part A (600 mg)</title>
            <description>600 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Non-Zero Concentration (AUC0-t) (Part A)</title>
          <units>µg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5119" spread="15.7"/>
                    <measurement group_id="O2" value="3.138" spread="13.7"/>
                    <measurement group_id="O3" value="12.91" spread="38.2"/>
                    <measurement group_id="O4" value="35.16" spread="16.9"/>
                    <measurement group_id="O5" value="118.8" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Non-Zero Concentration (AUC0-t) (Part B)</title>
        <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
            <description>450 mg twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Non-Zero Concentration (AUC0-t) (Part B)</title>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5040" spread="30.6"/>
                    <measurement group_id="O2" value="37000" spread="22.5"/>
                    <measurement group_id="O3" value="47500" spread="17.1"/>
                    <measurement group_id="O4" value="124000" spread="41.9"/>
                    <measurement group_id="O5" value="202000" spread="26.6"/>
                    <measurement group_id="O6" value="235000" spread="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time Zero to 24-hour Post-Dose (AUC0-24) (Part A)</title>
        <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part A (10mg)</title>
            <description>10 milligrams (mg)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part A (50 mg)</title>
            <description>50 mg</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part A (150 mg)</title>
            <description>150 mg</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part A (300 mg)</title>
            <description>300 mg</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part A (600 mg)</title>
            <description>600 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time Zero to 24-hour Post-Dose (AUC0-24) (Part A)</title>
          <units>µg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.551" spread="16.5"/>
                    <measurement group_id="O2" value="3.15" spread="11.6"/>
                    <measurement group_id="O3" value="12.6" spread="38.0"/>
                    <measurement group_id="O4" value="34.4" spread="16.9"/>
                    <measurement group_id="O5" value="110" spread="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time Zero to 24-hour Post-Dose (AUC0-24) (Parts B)</title>
        <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24 hours post dose starting on Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
            <description>450 mg twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time Zero to 24-hour Post-Dose (AUC0-24) (Parts B)</title>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5040" spread="30.6"/>
                    <measurement group_id="O2" value="34600" spread="21.7"/>
                    <measurement group_id="O3" value="45700" spread="16.9"/>
                    <measurement group_id="O4" value="111000" spread="39.0"/>
                    <measurement group_id="O5" value="184000" spread="25.2"/>
                    <measurement group_id="O6" value="210000" spread="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) (Part A)</title>
        <time_frame>Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part A (10mg)</title>
            <description>10 milligrams (mg)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part A (50 mg)</title>
            <description>50 mg</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part A (150 mg)</title>
            <description>150 mg</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part A (300 mg)</title>
            <description>300 mg</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part A (600 mg)</title>
            <description>600 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) (Part A)</title>
          <units>µg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.555" spread="16.7"/>
                    <measurement group_id="O2" value="3.19" spread="12.1"/>
                    <measurement group_id="O3" value="13.0" spread="41.2"/>
                    <measurement group_id="O4" value="35.4" spread="17.5"/>
                    <measurement group_id="O5" value="119" spread="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) (Part B)</title>
        <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
            <description>450 mg twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) (Part B)</title>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3150" spread="20.1"/>
                    <measurement group_id="O2" value="13500" spread="14.8"/>
                    <measurement group_id="O3" value="31800" spread="21.9"/>
                    <measurement group_id="O4" value="69300" spread="31.4"/>
                    <measurement group_id="O5" value="79000" spread="19.5"/>
                    <measurement group_id="O6" value="127000" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Drug Concentration (Cmax) (Part A)</title>
        <time_frame>Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part A (10mg)</title>
            <description>10 milligrams (mg)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part A (50 mg)</title>
            <description>50 mg</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part A (150 mg)</title>
            <description>150 mg</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part A (300 mg)</title>
            <description>300 mg</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part A (600 mg)</title>
            <description>600 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Drug Concentration (Cmax) (Part A)</title>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.121" spread="8.4"/>
                    <measurement group_id="O2" value="0.600" spread="35.4"/>
                    <measurement group_id="O3" value="2.47" spread="39.9"/>
                    <measurement group_id="O4" value="5.08" spread="17.6"/>
                    <measurement group_id="O5" value="11.5" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Drug Concentration (Cmax) (Part B)</title>
        <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
            <description>450 mg twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Drug Concentration (Cmax) (Part B)</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="785" spread="45.8"/>
                    <measurement group_id="O2" value="37.90" spread="28.1"/>
                    <measurement group_id="O3" value="62.80" spread="10.6"/>
                    <measurement group_id="O4" value="10800" spread="31.5"/>
                    <measurement group_id="O5" value="16300" spread="25.9"/>
                    <measurement group_id="O6" value="18200" spread="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Observed Cmax (Tmax) (Part A)</title>
        <time_frame>Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part A (10mg)</title>
            <description>10 milligrams (mg)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part A (50 mg)</title>
            <description>50 mg</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part A (150 mg)</title>
            <description>150 mg</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part A (300 mg)</title>
            <description>300 mg</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part A (600 mg)</title>
            <description>600 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Observed Cmax (Tmax) (Part A)</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.999" upper_limit="1.02"/>
                    <measurement group_id="O2" value="1.51" lower_limit="0.476" upper_limit="4.50"/>
                    <measurement group_id="O3" value="1.02" lower_limit="0.466" upper_limit="4.55"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.00" upper_limit="4.50"/>
                    <measurement group_id="O5" value="1.00" lower_limit="0.998" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Observed Cmax (Tmax) (Part B)</title>
        <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
            <description>450 mg twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Observed Cmax (Tmax) (Part B)</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="4.5"/>
                    <measurement group_id="O2" value="2.00" lower_limit="2.00" upper_limit="4.5"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.99" upper_limit="2.00"/>
                    <measurement group_id="O4" value="3.25" lower_limit="0.999" upper_limit="6.00"/>
                    <measurement group_id="O5" value="2.00" lower_limit="1.00" upper_limit="4.50"/>
                    <measurement group_id="O6" value="4.5" lower_limit="2.00" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Half-Life (T1/2) (Part A)</title>
        <time_frame>Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part A (10mg)</title>
            <description>10 milligrams (mg)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part A (50 mg)</title>
            <description>50 mg</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part A (150 mg)</title>
            <description>150 mg</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part A (300 mg)</title>
            <description>300 mg</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part A (600 mg)</title>
            <description>600 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-Life (T1/2) (Part A)</title>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.32" spread="8.8"/>
                    <measurement group_id="O2" value="3.77" spread="23.9"/>
                    <measurement group_id="O3" value="5.22" spread="25.3"/>
                    <measurement group_id="O4" value="5.25" spread="25.8"/>
                    <measurement group_id="O5" value="5.47" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Half-Life (T1/2) (Part B)</title>
        <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
            <description>450 mg twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-Life (T1/2) (Part B)</title>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" spread="12.1"/>
                    <measurement group_id="O2" value="6.16" spread="15.16"/>
                    <measurement group_id="O3" value="5.24" spread="20.3"/>
                    <measurement group_id="O4" value="5.94" spread="14.9"/>
                    <measurement group_id="O5" value="5.12" spread="18.5"/>
                    <measurement group_id="O6" value="6.26" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance of Drug (CL/F) (Part A)</title>
        <time_frame>Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part A (10mg)</title>
            <description>10 milligrams (mg)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part A (50 mg)</title>
            <description>50 mg</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part A (150 mg)</title>
            <description>150 mg</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part A (300 mg)</title>
            <description>300 mg</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part A (600 mg)</title>
            <description>600 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance of Drug (CL/F) (Part A)</title>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.27" spread="3.17"/>
                    <measurement group_id="O2" value="15.78" spread="2.18"/>
                    <measurement group_id="O3" value="12.16" spread="4.16"/>
                    <measurement group_id="O4" value="8.59" spread="1.37"/>
                    <measurement group_id="O5" value="5.27" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance of Drug (CL/F) (Part B)</title>
        <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
            <description>450 mg twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance of Drug (CL/F) (Part B)</title>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="3.57"/>
                    <measurement group_id="O2" value="5.20" spread="1.14"/>
                    <measurement group_id="O3" value="6.64" spread="1.10"/>
                    <measurement group_id="O4" value="4.27" spread="1.35"/>
                    <measurement group_id="O5" value="3.23" spread="0.76"/>
                    <measurement group_id="O6" value="3.97" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Total Volume of Distribution (VZ/F) (Part A)</title>
        <time_frame>Pre-dose, 0.5, 1, 2, 4.5, 6, 8.5, 12.5, 24, 28.5, 48, 96 and 144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part A (10mg)</title>
            <description>10 milligrams (mg)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part A (50 mg)</title>
            <description>50 mg</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part A (150 mg)</title>
            <description>150 mg</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part A (300 mg)</title>
            <description>300 mg</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part A (600 mg)</title>
            <description>600 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Volume of Distribution (VZ/F) (Part A)</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.87" spread="10.765"/>
                    <measurement group_id="O2" value="86.35" spread="15.326"/>
                    <measurement group_id="O3" value="88.09" spread="17.282"/>
                    <measurement group_id="O4" value="66.97" spread="20.368"/>
                    <measurement group_id="O5" value="41.43" spread="13.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Total Volume of Distribution (VZ/F) (Part B)</title>
        <time_frame>Predose, 0.5, 1, 2, 4.5, 6, 8.5, 12, 13, 14, 16, 24, 48, 168, and 336 hours post dose starting on Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
            <description>450 mg twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Volume of Distribution (VZ/F) (Part B)</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6" spread="39.15"/>
                    <measurement group_id="O2" value="46.3" spread="10.18"/>
                    <measurement group_id="O3" value="51.2" spread="14.76"/>
                    <measurement group_id="O4" value="36.8" spread="12.39"/>
                    <measurement group_id="O5" value="24.2" spread="7.055"/>
                    <measurement group_id="O6" value="35.8" spread="12.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Drug Excreted in Urine (Aet1-t12) (Part A)</title>
        <description>Data Not Collected for this Parameter</description>
        <time_frame>Pre-Dose and 12 hours Post-Dose</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part A (10mg)</title>
            <description>10 milligrams (mg)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part A (50 mg)</title>
            <description>50 mg</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part A (150 mg)</title>
            <description>150 mg</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part A (300 mg)</title>
            <description>300 mg</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part A (600 mg)</title>
            <description>600 mg</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part A Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Amount of Drug Excreted in Urine (Aet1-t12) (Part A)</title>
          <description>Data Not Collected for this Parameter</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Drug Excreted in Urine (Aet1-t12) (Part B)</title>
        <description>Data Not Collected for this Parameter</description>
        <time_frame>Pre-Dose and 12 hours Post-Dose on Day 28</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50 mg, Twice a Day)</title>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
          </group>
          <group group_id="O7">
            <title>GLWL-01 Part B Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Amount of Drug Excreted in Urine (Aet1-t12) (Part B)</title>
          <description>Data Not Collected for this Parameter</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Drug Excreted in Urine (Aet0-24) (Part A)</title>
        <time_frame>Pre-Dose and 24-hours Post-Dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part A (10mg)</title>
            <description>10 milligrams (mg)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part A (50 mg)</title>
            <description>50 mg</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part A (150 mg)</title>
            <description>150 mg</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part A (300 mg)</title>
            <description>300 mg</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part A (600 mg)</title>
            <description>600 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Drug Excreted in Urine (Aet0-24) (Part A)</title>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.611"/>
                    <measurement group_id="O2" value="11.7" spread="2.56"/>
                    <measurement group_id="O3" value="36.9" spread="12.1"/>
                    <measurement group_id="O4" value="101" spread="15.2"/>
                    <measurement group_id="O5" value="191" spread="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Drug Excreted in Urine (Aet0-24) (Part B)</title>
        <time_frame>Pre-Dose and 24-hours Post-Dose on Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
            <description>450 mg twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Drug Excreted in Urine (Aet0-24) (Part B)</title>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2" spread="12.87"/>
                    <measurement group_id="O2" value="94.8" spread="9.843"/>
                    <measurement group_id="O3" value="125" spread="33.45"/>
                    <measurement group_id="O4" value="175" spread="25.93"/>
                    <measurement group_id="O5" value="272" spread="67.08"/>
                    <measurement group_id="O6" value="293" spread="77.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fraction of Drug Excreted in the Urine (Fe) (Part A)</title>
        <time_frame>Pre-Dose and 24-hours Post-Dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part A (10mg)</title>
            <description>10 milligrams (mg)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part A (50 mg)</title>
            <description>50 mg</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part A (150 mg)</title>
            <description>150 mg</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part A (300 mg)</title>
            <description>300 mg</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part A (600 mg)</title>
            <description>600 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Drug Excreted in the Urine (Fe) (Part A)</title>
          <units>percentage of the drug</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="6.11"/>
                    <measurement group_id="O2" value="23.3" spread="5.13"/>
                    <measurement group_id="O3" value="24.6" spread="8.08"/>
                    <measurement group_id="O4" value="33.6" spread="5.07"/>
                    <measurement group_id="O5" value="31.8" spread="6.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fraction of Drug Excreted in the Urine (Fe) (Part B)</title>
        <time_frame>Pre-Dose and 24-hours Post-Dose on Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
            <description>450 mg twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Drug Excreted in the Urine (Fe) (Part B)</title>
          <units>percentage of the drug</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3" spread="25.74"/>
                    <measurement group_id="O2" value="63.2" spread="6.562"/>
                    <measurement group_id="O3" value="41.5" spread="11.15"/>
                    <measurement group_id="O4" value="38.9" spread="5.761"/>
                    <measurement group_id="O5" value="60.5" spread="14.91"/>
                    <measurement group_id="O6" value="48.9" spread="12.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Plasma Glucose Concentration After Multiple Doses (Part B)</title>
        <time_frame>Baseline to Day 24-26</time_frame>
        <population>The 450 mg twice a day arm had no usable continuous glucose data, due to technical difficulties</population>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01, Part B (450 mg Twice a Day)</title>
            <description>450 mg twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
          <group group_id="O7">
            <title>Placebo Part B</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Plasma Glucose Concentration After Multiple Doses (Part B)</title>
          <population>The 450 mg twice a day arm had no usable continuous glucose data, due to technical difficulties</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.53" spread="23.0"/>
                    <measurement group_id="O2" value="7.38" spread="40.4"/>
                    <measurement group_id="O3" value="7.92" spread="30.3"/>
                    <measurement group_id="O4" value="21.39" spread="13.5"/>
                    <measurement group_id="O6" value="5.43" spread="38.0"/>
                    <measurement group_id="O7" value="8.05" spread="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postprandial Glucose (Part B)</title>
        <description>Mixed Meal Tolerance Test (4.5 hours after a meal on Day 28); Baseline Adjusted. The day 28 values were used for analysis; change from baseline was calculated on Day 28.</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01, Part B (450 mg, Twice a Day)</title>
            <description>450 mg, twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
          <group group_id="O7">
            <title>Placebo Part B</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postprandial Glucose (Part B)</title>
          <description>Mixed Meal Tolerance Test (4.5 hours after a meal on Day 28); Baseline Adjusted. The day 28 values were used for analysis; change from baseline was calculated on Day 28.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="11.70"/>
                    <measurement group_id="O2" value="11.6" spread="27.74"/>
                    <measurement group_id="O3" value="-13.7" spread="33.16"/>
                    <measurement group_id="O4" value="10.7" spread="27.40"/>
                    <measurement group_id="O5" value="29.3" spread="49.43"/>
                    <measurement group_id="O6" value="29.7" spread="25.77"/>
                    <measurement group_id="O7" value="13.2" spread="41.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-Peptide Concentration (Part B)</title>
        <description>Mixed Meal Tolerance Test (4.5 hours after a meal on Day 28); Baseline-Adjusted. The day 28 values were used for analysis; change from baseline was calculated on Day 28.</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01, Part B (450 mg, Twice a Day)</title>
            <description>450 mg, twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
          <group group_id="O7">
            <title>Placebo Part B</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-Peptide Concentration (Part B)</title>
          <description>Mixed Meal Tolerance Test (4.5 hours after a meal on Day 28); Baseline-Adjusted. The day 28 values were used for analysis; change from baseline was calculated on Day 28.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.373" spread="0.257"/>
                    <measurement group_id="O2" value="0.338" spread="0.9523"/>
                    <measurement group_id="O3" value="0.437" spread="0.5171"/>
                    <measurement group_id="O4" value="0.575" spread="1.0658"/>
                    <measurement group_id="O5" value="0.360" spread="1.3600"/>
                    <measurement group_id="O6" value="0.457" spread="0.8498"/>
                    <measurement group_id="O7" value="0.043" spread="0.6513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin Concentration (Part B)</title>
        <description>4.5 hours following Mixed Meal Tolerance Test (MMTT) on Day 28; Baseline Adjusted. The day 28 values were used for analysis; change from baseline was calculated on Day 28.</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
            <description>450 mg, twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
          <group group_id="O7">
            <title>Placebo Part B</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Concentration (Part B)</title>
          <description>4.5 hours following Mixed Meal Tolerance Test (MMTT) on Day 28; Baseline Adjusted. The day 28 values were used for analysis; change from baseline was calculated on Day 28.</description>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.60" spread="7.579"/>
                    <measurement group_id="O2" value="-3.89" spread="11.533"/>
                    <measurement group_id="O3" value="-9.75" spread="10.687"/>
                    <measurement group_id="O4" value="2.12" spread="5.878"/>
                    <measurement group_id="O5" value="1.27" spread="9.194"/>
                    <measurement group_id="O6" value="0.23" spread="7.653"/>
                    <measurement group_id="O7" value="2.39" spread="8.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Glucose Concentration (Part B)</title>
        <description>Fasting glucose concentration after 28 day treatment</description>
        <time_frame>Baseline to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
            <description>450 mg, twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
          <group group_id="O7">
            <title>Placebo Part B</title>
          </group>
        </group_list>
        <measure>
          <title>Fasting Glucose Concentration (Part B)</title>
          <description>Fasting glucose concentration after 28 day treatment</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="1.139"/>
                    <measurement group_id="O2" value="1.10" spread="1.520"/>
                    <measurement group_id="O3" value="-0.20" spread="2.100"/>
                    <measurement group_id="O4" value="0.63" spread="0.299"/>
                    <measurement group_id="O5" value="-1.13" spread="1.381"/>
                    <measurement group_id="O6" value="-0.10" spread="2.104"/>
                    <measurement group_id="O7" value="0.91" spread="2.116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weight (Part B)</title>
        <time_frame>Baseline to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
            <description>450 mg, twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
          <group group_id="O7">
            <title>Placebo Part B</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight (Part B)</title>
          <units>kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.375" spread="0.763"/>
                    <measurement group_id="O2" value="-0.340" spread="0.786"/>
                    <measurement group_id="O3" value="-0.150" spread="0.995"/>
                    <measurement group_id="O4" value="-0.417" spread="0.741"/>
                    <measurement group_id="O5" value="0.417" spread="1.229"/>
                    <measurement group_id="O6" value="0.350" spread="0.356"/>
                    <measurement group_id="O7" value="-0.025" spread="0.717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist Circumference (Part B)</title>
        <time_frame>Baseline to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
            <description>450 mg, twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
          <group group_id="O7">
            <title>Placebo Part B</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Waist Circumference (Part B)</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.275" spread="3.522"/>
                    <measurement group_id="O2" value="1.360" spread="5.755"/>
                    <measurement group_id="O3" value="-3.517" spread="4.001"/>
                    <measurement group_id="O4" value="-1.383" spread="5.123"/>
                    <measurement group_id="O5" value="-1.250" spread="1.091"/>
                    <measurement group_id="O6" value="-0.083" spread="0.492"/>
                    <measurement group_id="O7" value="-0.867" spread="4.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hip Circumference (Part B)</title>
        <time_frame>Baseline to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GLWL-01 Part B (50mg, Twice a Day)</title>
            <description>50 milligrams (mg), twice a day (BID)</description>
          </group>
          <group group_id="O2">
            <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
            <description>150 mg, twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>GLWL-01 Part B (300 mg, Once a Day)</title>
            <description>300 mg, once a day (QD)</description>
          </group>
          <group group_id="O4">
            <title>GLWL-01 Part B (450 mg, Once a Day)</title>
            <description>450 mg once a day (QD)</description>
          </group>
          <group group_id="O5">
            <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
            <description>450 mg, twice a day (BID)</description>
          </group>
          <group group_id="O6">
            <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
            <description>600 mg, twice a day (BID)</description>
          </group>
          <group group_id="O7">
            <title>Placebo Part B</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hip Circumference (Part B)</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" spread="2.940"/>
                    <measurement group_id="O2" value="0.960" spread="7.442"/>
                    <measurement group_id="O3" value="1.283" spread="2.337"/>
                    <measurement group_id="O4" value="-0.417" spread="2.094"/>
                    <measurement group_id="O5" value="0.167" spread="0.753"/>
                    <measurement group_id="O6" value="-0.333" spread="0.516"/>
                    <measurement group_id="O7" value="0.192" spread="6.860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>GLWL-01, Part A (10mg)</title>
          <description>10 milligrams (mg)</description>
        </group>
        <group group_id="E2">
          <title>GLWL-01 Part A (50 mg)</title>
          <description>50 mg</description>
        </group>
        <group group_id="E3">
          <title>GLWL-01 Part A (150 mg)</title>
          <description>150 mg</description>
        </group>
        <group group_id="E4">
          <title>GLWL-01 Part A (300 mg)</title>
          <description>300 mg</description>
        </group>
        <group group_id="E5">
          <title>GLWL-01 Part A (600 mg)</title>
          <description>600 mg</description>
        </group>
        <group group_id="E6">
          <title>GLWL-01 Part A Placebo</title>
        </group>
        <group group_id="E7">
          <title>GLWL-01 Part B (50 mg, Twice a Day)</title>
        </group>
        <group group_id="E8">
          <title>GLWL-01 Part B (150 mg, Twice a Day)</title>
        </group>
        <group group_id="E9">
          <title>GLWL-01 Part B (300 mg, Once a Day)</title>
        </group>
        <group group_id="E10">
          <title>GLWL-01 Part B (450 mg, Once a Day)</title>
        </group>
        <group group_id="E11">
          <title>GLWL-01 Part B (450 mg, Twice a Day)</title>
        </group>
        <group group_id="E12">
          <title>GLWL-01 Part B (600 mg, Twice a Day)</title>
        </group>
        <group group_id="E13">
          <title>GLWL-01 Part B Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Faeces Discolored</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Faeces Soft</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Catheter site paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Medical Device Site Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Glucose Increase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood Lactate Dehydrogenase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Limb Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E7" events="5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinitis Allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Palmar Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>GLWL Research Inc</organization>
      <email>choruspharma@lists.lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

